|

Cancer Survivors Program

RECRUITINGN/ASponsored by Masaryk Memorial Cancer Institute
Actively Recruiting
PhaseN/A
SponsorMasaryk Memorial Cancer Institute
Started2025-05-05
Est. completion2025-12-12
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* The patient understands the information provided and agrees to participate in the study.
* Age 18 years or older.
* Histologically confirmed invasive breast cancer or invasive prostate cancer.
* Completion of the acute phase of curative oncological therapy:

  * for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated
  * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy
* The patient is available for follow-up within 12 months of enrollment in the study.

Exclusion Criteria:

* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)
* Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer).
* Recurrence of cancer
* Metastatic disease
* History of other primary malignancy (except for non-melanoma skin cancer)

Conditions4

Breast CancerBreast Cancer PatientsCancerProstate Cancer Patients

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.